RxDoctor Payments DataLook up a doctor →

Viplove Senadhi, DO

Gastroenterology · Montgomery, ALNPI 1174785562

Payments from drug & device makers

$282,416in general payments, 2019–2025

Across 868 payments — averaging $325.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Evoke Pharma, Inc.$192K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$62K
  • Redhill Biopharma Inc.$16K
  • AbbVie$5K
  • Gilead$3K
  • Pfizer$595
  • plus $4K from 33 others

What the payments were for

  • Consulting fees$6,5812%
  • Speaking & faculty fees$206,32373%
  • Travel & lodging$48,43517%
  • Food & beverage$20,9777%
  • Gifts$1000%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$282,416 in reported general payments places this provider in the 90th percentile of 225 gastroenterology providers in Alabama.

See all gastroenterology providers in Alabama

Medicare billing

Part B allowed, 2024
$70,840
Medicare patients
102
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab16$241,023
Ursodiol37$148,825
XifaxanRifaximin47$142,580
RelistorMethylnaltrexone Bromide20$100,358
LinzessLinaclotide72$74,723
TrulancePlecanatide32$31,413
IbsrelaTenapanor Hcl16$31,327
VemlidyTenofovir Alafenamide14$20,919
Dexlansoprazole DrDexlansoprazole16$5,986
Famotidine124$2,775
Sucralfate20$2,416
Pantoprazole Sodium167$2,415
Metoclopramide Hcl47$2,067
Omeprazole77$1,465
Colchicine12$1,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance$61,795$274,35199 claims
AbbVieLinzess$4,896$74,72372 claims
Ardelyx, Inc.Ibsrela$358$31,32716 claims
GileadVemlidy$2,686$20,91914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 225 gastroenterology providers in Alabama.

Other gastroenterology in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →